Related Experiment Video
Updated: Feb 12, 2026

Generation of Multicellular Human Primary Endometrial Organoids
Published on: October 4, 2019
17β-Hydroxysteroid Dehydrogenase Type 2 Expression Is Induced by Androgen Signaling in Endometrial Cancer
Chiaki Hashimoto1, Yasuhiro Miki2, Sota Tanaka3
1Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan. chiaki@med.tohoku.ac.jp.
Abstract:
Endometrial cancer is one of the most common female pelvic cancers and has been considered an androgen-related malignancy. Several studies have demonstrated the anti-cell proliferative effect of androgen on endometrial cancer cells; however, the mechanisms of the anti-cancer effect of androgen remain largely unclear. 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2), which catalyzes the conversion of E2 to E1, is known to be upregulated by androgen treatment in breast cancer cells. In this study, we therefore focused on the role of androgen on estrogen dependence in endometrial cancer. Dihydrotestosterone (DHT) was found to induce 17β-HSD2 mRNA and protein expression in HEC-1B endometrial cancer cells. DHT could also inhibit cell proliferation of HEC-1B when induced by estradiol treatment. In 19 endometrioid endometrial adenocarcinoma (EEA) tissues, intratumoral DHT concentration was measured by liquid chromatography/electrospray tandem mass spectrometry and was found to be significantly correlated with 17β-HSD2 immunohistochemical status. We further examined the correlations between 17β-HSD2 immunoreactivity and clinicopathological parameters in 53 EEA tissues. 17β-HSD2 status was inversely associated with the histological grade, clinical stage, and cell proliferation marker Ki-67, and positively correlated with progesterone receptor expression. 17β-HSD2 status tended to be positively associated with androgen receptor status. In 53 EEA cases, the 17β-HSD2-positive group tended to have better prognosis than that for the negative group with respect to progression-free survival and endometrial cancer-specific survival. These findings suggest that androgen suppresses the estrogen dependence of endometrial cancer through the induction of 17β-HSD2 in endometrial cancer.
Insights
Androgen suppresses endometrial cancer growth by increasing 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2). This enzyme reduces estrogen
Area of Science:
- Gynecologic Oncology
- Endocrinology
- Cancer Biology
Background:
- Endometrial cancer is a common female pelvic cancer linked to androgens.
- Androgen's anti-cancer mechanisms in endometrial cancer are not fully understood.
- 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) converts estradiol (E2) to estrone (E1) and is upregulated by androgens in breast cancer.
Purpose of the Study:
- To investigate the role of androgens in endometrial cancer's estrogen dependence.
- To explore the function of 17β-HSD2 in androgen-mediated effects on endometrial cancer.
Main Methods:
- Dihydrotestosterone (DHT) treatment of HEC-1B endometrial cancer cells to assess 17β-HSD2 expression and proliferation.
- Measurement of intratumoral DHT levels in endometrioid endometrial adenocarcinoma (EEA) tissues.
- Immunohistochemical analysis of 17β-HSD2, Ki-67, progesterone receptors, and androgen receptors in EEA tissues.
- Correlation analysis between 17β-HSD2 status and clinicopathological parameters and patient survival.
Main Results:
- DHT induced 17β-HSD2 mRNA and protein expression in HEC-1B cells.
- DHT inhibited estradiol-induced proliferation of HEC-1B cells.
- Intratumoral DHT levels correlated with 17β-HSD2 status in EEA tissues.
- 17β-HSD2 expression was inversely associated with tumor grade, stage, and Ki-67, and positively correlated with progesterone receptor and androgen receptor status.
- 17β-HSD2-positive patients showed improved progression-free and cancer-specific survival.
Conclusions:
- Androgen suppresses endometrial cancer estrogen dependence by inducing 17β-HSD2.
- 17β-HSD2 may serve as a biomarker for better prognosis in endometrial cancer.
- Targeting the androgen-estrogen-17β-HSD2 axis could offer therapeutic strategies for endometrial cancer.
More Related Videos
Related Concept Videos
Types of Signaling Molecules
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Diabetes Mellitus: Type 2 and Gestational
Cell Specific Gene Expression
Bacterial Signaling
Mechanisms of Retrovirus-induced Cancers

